KRM Ayurveda IPO
Market Sentiment
Market Lot Size
IPO Details
IPO Reservation
Financial Analysis
| Metric | 2023 | 2024 | 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 89.38 | 67.57 | 76.95 | 48.65 |
| Expense | 79.29 | 62.85 | 60.61 | 37.65 |
| Profit (PAT) | 7.60 | 3.41 | 12.10 | 8.14 |
| Total Assets | 39.48 | 43.91 | 66.79 | 78.12 |
| Company | P/E | EPS | Market Cap (Cr) |
|---|---|---|---|
| Jeena Sikho Lifecare Ltd. | 76.58 | 8.86 | 31 |
| Vaidya Sane Ayurved Laboratories Ltd | 93.20 | 3.07 | 5 |
Promoters: Mr. Puneet Dhawan and Mrs. Tanya Dhawan
| Shareholding | No. of Shares | Holding % |
|---|---|---|
| Promoter Holding Pre Issue | 1,55,20,800 | 92.16% |
| Promoter Holding Post Issue | 2,12,60,800 | 67.28% |
Company Information
KRM Ayurveda Ltd started its journey on 3 September 2019, with the work of manufacturing Ayurvedic products, herbal and botanical remedies, medicines, supplements, and possibly skin care / wellness-related items. The company has many hospitals and clinics across India, not only in India, but it also provides telemedicine services and sales abroad. Presently, the company runs 6 (Six) Hospitals and 5 (Five) Clinics at different locations in the country. The company has good services for the patient, including In-Patient & Out-Patient Care, Panchakarma Therapies, Specialized Clinics, Medicinal Sales, Diet & Lifestyle Counseling.
| Purpose | Amount (Cr) |
|---|---|
| Capital Expenditure for Construction and Development of Telemedicine Operational Facilities | 13.67 |
| Purchase of CRM Software and Hardware Infrastructure | 1.42 |
| Human Resources | 5.44 |
| Repayment/Prepayment of loan | 12.50 |
| Working Capital Requirement | 18.00 |
| General Corporate Purpose | - |
Resources & Documents
KRM Ayurveda Ltd., A-16, G T Karnal road, North West Delhi, New Delhi, 110033
KRM Ayurveda has set a price band of Rs 129–Rs 135 per share for an issue size of Rs 77 crore in the ayurveda & healthcare sector. The stock listed with a 33.85% gain versus its issue price on January 29, 2026.
KRM Ayurveda Ltd started its journey on 3 September 2019, with the work of manufacturing Ayurvedic products, herbal and botanical remedies, medicines, supplements, and possibly skin care / wellness-related items. The company has many hospitals and clinics across India, not only in India, but it also provides telemedicine services and sales abroad. The company operates in the ayurveda & healthcare space.
The issue is promoted by Mr. Puneet Dhawan and Mrs. Tanya Dhawan with NEXGEN Financial Solutions Pvt. Ltd. acting as lead manager. Net proceeds will primarily be used towards Capital Expenditure for Construction and Development of Telemedicine Operational Facilities (Rs 14 crore) and Purchase of CRM Software and Hardware Infrastructure (Rs 1 crore).
Grey market is quoting a premium of +Rs 45 (+33.3% over issue price), up Rs 10 from the previous session. Final subscription data records overall subscription at 74.43x, retail at 54.21x, QIB at 63.31x, NII at 136.10x.
On fundamentals, the company is posting revenue growth of 13.9%, a profit margin of 15.7%, return on equity of 67.9% in its most recent reported period. Listed peers in this segment include Jeena Sikho Lifecare Ltd. (P/E 76.58x, market cap Rs 31 crore) and Vaidya Sane Ayurved Laboratories Ltd (P/E 93.20x, market cap Rs 5 crore) — useful reference points when evaluating the issue's pricing relative to where the broader sector are trading.
Our data-driven engine currently flags this issue as a Subscribe call — the composite picture tilts favourable, though not without some caveats. Past performance does not predict future returns — review the price chart and peer comparison below before trading.
Understanding Grey Market Premium (GMP)
The Grey Market Premium (GMP) is an unofficial indicator of how an IPO's shares are trading in the grey market before they are officially listed on a stock exchange. It reflects investor sentiment and demand for the IPO shares ahead of listing day.
How does it work? The grey market is an informal, over-the-counter market where investors buy and sell IPO shares before the official listing date. If an IPO has a positive GMP, it suggests that investors expect the stock to list above its issue price. A negative GMP indicates expectations of a listing below the issue price.
Example: If an IPO has an issue price of ₹100 and the GMP is ₹50, the expected listing price would be approximately ₹150 (issue price + GMP). This translates to an estimated listing gain of 50%.
Factors that influence GMP:
- Subscription levels — Higher subscription typically drives GMP up
- Market conditions — Bullish markets tend to boost GMP across all IPOs
- Company fundamentals — Strong financials and growth potential attract premium
- Industry sentiment — Positive outlook for the sector can increase demand
- IPO pricing — Reasonably priced IPOs relative to peers tend to command higher GMP
Disclaimer: GMP is an unofficial metric from the grey market and is not regulated by SEBI or any stock exchange. GMP values fluctuate frequently and should not be the sole basis for investment decisions. Always consider company fundamentals, financial health, and your own risk appetite before investing in any IPO.
Related IPO
No comments yet. Be the first to share your opinion!